Hemlibra Injection 30MG 60MG Roche by MedEsy

Hemlibra 150mg/0.7ml Injection consists of the active ingredient Emicizumab. It is indicated to treat Haemophilia A. Heamophilia A is a genetic bleeding condition caused by a lack of factor VIII, which is essential factor for blood clotting.

The liver synthesizes factor VIII. Its deficiency affects one in ten thousand individuals. This can lead to bleeding disorder and in severe cases, bleeding may occur in your skin, muscle and joints. Frequent bleeding, especially in the joints, alters the physical and mental well-being of the patients and caregivers.

Inform your physician before taking this medicine if you are taking other medicines that help in blood clotting.

Uses of Hemlibra 150mg/0.7ml Injection:

• Treatment of Haemophilia A

How Hemlibra 150mg/0.7ml Injection works:

Hemlibra 150mg/0.7ml Injection restores the function of Factor VIII to ensure proper blood clotting takes place. It is a monoclonal antibody that mimics the activity of factor VIII in generating the blood clotting factors. This medicine prevents or decreases bleeding episodes in patients with Haemophilia A.

Interaction with other drugs:

Inform your physician regarding any medicines you are taking or have taken before the treatment.

More Information:

Store in a refrigerator at 2°C to 8°C. Do not freeze.

References:

1. Roche Products Ltd., Electronic Medicines Compendium (EMC), [Revised on Aug 2020] [Accessed on 16th Aug 2021], https://www.medicines.org.uk/emc/files/pil.9042.pdf
2. Genentech, Inc., [Revised on Mar 2021] [Accessed on 16th Aug 2021], https://www.gene.com/download/pdf/hemlibra_prescribing.pdf
3. H.G. Watson, J.I.O. Craig, L.M. Manson, Blood disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 989-1056.
4. Le Quellec, Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A, Drug Design, Development and Therapy, 2020:14, https://www.dovepress.com/getfile.php?fileID=55818